Text or WhatsApp Richard at (808) 600-9260
Lion crestHealthcareInvestmentBanking.com

Rollover Equity Calculator: What Your Rolled Stake Could Be Worth at the Second Sale

Your rolled stake is worth your ownership share of the equity left at the second sale. That equity is exit EBITDA times the exit multiple, less remaining debt and the management pool. In our hypothetical $30 million dental deal, a $6 million roll becomes about $16.2 million in five years. That is a 2.70x return and a 21.9% IRR. Put the sponsor's cash in an 8% preferred and hold EBITDA flat, and the same roll returns about half its cost.

Estimate only. Educational, not investment advice.

Data as of November 20, 2026. Each market figure names its source, population and period beside it. All worked examples are hypothetical and are our arithmetic.

The 9 inputs and where to find each one

Input What to enter Where to find it
Entry enterprise value Headline price for 100% of the business, before debt payoff and fees LOI or purchase agreement
Entry EBITDA multiple Price divided by the adjusted EBITDA the buyer underwrote LOI, banker's teaser, quality of earnings report
Debt at close (% of EV) Acquisition debt as a share of enterprise value Sources and uses table, credit commitment letter
Rollover amount Dollar value of the equity you take instead of cash LOI rollover clause, contribution agreement
Annual EBITDA growth Expected yearly EBITDA growth, organic plus add-ons Sponsor's model, your own budget
Years to second sale Expected hold until the sponsor sells Sponsor's fund strategy and hold history
Exit multiple EBITDA multiple you expect at the second sale Comparable sponsor-to-sponsor deals, benchmarks below
Debt paid down by exit Share of entry debt repaid before the exit Sponsor's model, credit agreement amortization and cash sweep terms
Management incentive pool Effective share of exit equity paid to management. For profits interests above a threshold, use the conversion in the adjustments section Draft LLC agreement, incentive plan term sheet

Three assumptions sit under every output. Your rollover is common equity bought at the same unit price as the sponsor's cash. The sponsor's cash and your roll make up all of the entry equity. Paydown is a single percentage you choose. If co-investors, management or equity-funded fees add units at close, compute ownership as your units divided by total units. If the credit agreement allows new borrowing for acquisitions, paydown can turn negative. Run 0% paydown as a floor.

The 9 outputs, defined exactly

Output Exact definition
Entry EBITDA Entry EV ÷ entry multiple
Entry equity Entry EV × (1 − debt %)
Ownership % Rollover amount ÷ entry equity
Exit EBITDA Entry EBITDA × (1 + growth)^years
Exit EV Exit EBITDA × exit multiple
Exit equity (Exit EV − entry debt × (1 − paydown %)) × (1 − effective management pool %)
Rolled stake value Ownership % × exit equity
MOIC Rolled stake value ÷ rollover amount
IRR MOIC^(1 ÷ years) − 1, assuming no interim distributions

All outputs are pre-tax and before exit fees. The tax and fee sections below show how to adjust.

Worked example: a $30 million dental platform sale with $6 million rolled

Example (hypothetical, our arithmetic). A multi-site dental group with $3 million of EBITDA sells to a sponsor at 10x. The sponsor funds $15 million of debt and $9 million of cash equity. You roll $6 million into the same class of units at $1.00 per unit. That gives 15,000,000 units at close, of which you hold 6,000,000. Your roll is 20% of the price and 40% of the equity. Management receives profits interests that take 8% of every dollar of equity value above a $15 million threshold, the entry equity value. Debt is 30% repaid by exit. Transaction fees are ignored.

Dental is a high-volume target. Of the 1,029 PE-backed U.S. healthcare deals the Private Equity Stakeholder Project tracked in 2025 (PitchBook and LevinPro HC data), 149 were in dental, and 95% of those were add-ons by PE-owned platforms. Sikich's Q3 2026 update gives indicative 2026 ranges of 9 to 11x EBITDA for DSO platforms and 5 to 8x for dental add-ons, so 10x is a platform price.

Step Calculation Result
Entry EBITDA $30,000,000 ÷ 10 $3,000,000
Debt at close $30,000,000 × 50% $15,000,000 (5.0x EBITDA)
Entry equity $9,000,000 sponsor + $6,000,000 roll $15,000,000 (15,000,000 units at $1.00)
Ownership 6,000,000 ÷ 15,000,000 units 40%
Exit EBITDA $3,000,000 × 1.10^5 $4,831,530
Exit EV $4,831,530 × 11 $53,146,830
Debt at exit $15,000,000 × (1 − 30%) $10,500,000
Equity before pool $53,146,830 − $10,500,000 $42,646,830
Profits interests 8% × ($42,646,830 − $15,000,000) $2,211,746
Equity to capital holders $42,646,830 − $2,211,746 $40,435,084
Rolled stake value $40,435,084 × 40% $16,174,033
MOIC $16,174,033 ÷ $6,000,000 2.70x
IRR 2.70^(1/5) − 1 21.9%

The pool takes 5.19% of exit equity here, not 8%. Entering a flat 8% pool in the calculator gives $15,694,033 and 2.62x, which understates the stake by about $480,000. Enter 5.19% to reproduce the table within rounding. This pool design is one common form. Some plans use a catch-up, tiered thresholds or a hurdle set above entry value, and each changes the dollar figure. Read the mechanics in the draft LLC agreement and rerun the conversion.

The 5.0x leverage is in line with the broader market. PitchBook data reported by Sikich puts 2025 entry leverage at 5.2x EBITDA for the median PE-backed U.S. healthcare services buyout. That population spans all services subsectors and larger companies, with a median implied EBITDA of about $33 million, so treat it as context for a $3 million dental platform, not as a benchmark.

How each assumption moves the result

Hypothetical, our arithmetic. Every row holds the other base case inputs, including 30% paydown and the profits-interest pool with its $15 million threshold.

Scenario Rolled stake value MOIC IRR
Base case (11x exit, 5 years) $16,174,033 2.70x 21.9%
Exit at 10x, flat to entry $14,396,030 2.40x 19.1%
Exit at 9x, one turn down $12,618,027 2.10x 16.0%
5% growth instead of 10% $12,115,163 2.02x 15.1%
No debt paydown $14,518,033 2.42x 19.3%
7-year hold, 10% growth continues, paydown held at 30% $20,281,220 3.38x 19.0%
7-year hold, EBITDA flat after year 5, paydown held at 30% $16,174,033 2.70x 15.2%

In this deal, halving growth costs more than losing two turns of multiple. Test the growth assumption first. A longer hold with continued growth raises MOIC but lowers IRR. A longer hold with stalled growth costs nearly seven points of IRR for the same dollars. The 7-year rows keep paydown at 30% for comparability. Two more years of amortization would lift both rows. Add-on borrowing in those years would cut them.

Sensitivity grid: growth against exit multiple

Hypothetical, our arithmetic. 5-year hold, 30% paydown, profits-interest pool, pari passu common. Each cell shows stake value, MOIC and IRR.

Annual EBITDA growth 9x exit 10x exit 11x exit
0% (EBITDA stays $3.0M) $6,552,000, 1.09x, 1.8% $7,656,000, 1.28x, 5.0% $8,760,000, 1.46x, 7.9%
5% (exit EBITDA $3.83M) $9,297,134, 1.55x, 9.2% $10,706,148, 1.78x, 12.3% $12,115,163, 2.02x, 15.1%
10% (exit EBITDA $4.83M) $12,618,027, 2.10x, 16.0% $14,396,030, 2.40x, 19.1% $16,174,033, 2.70x, 21.9%

Read the grid by row. Within this grid, each five-point step in growth adds more value than a full turn of exit multiple. At 9x, moving from 5% to 10% growth adds $3.32 million, while moving from 9x to 10x at 10% growth adds $1.78 million. The ratio depends on leverage, hold length and starting multiple, so rerun the grid with your own inputs. A flat business falls short of an 8% IRR even at 11x, a turn above its entry price.

Set the growth input against the market. CMS National Health Expenditure data show U.S. physician and clinical services spending grew 8.1% to $1,109.7 billion in 2024, and CMS projects that category to grow 5.5% a year on average from 2025 to 2034. Spending growth is not EBITDA growth, but the comparison is useful. The 5% row sits near the projected pace for the category. The 10% base case needs add-ons, new sites, margin gains or share gains on top of it. Ask the sponsor to split its growth rate into those pieces.

Breakeven exit multiple: what it takes to get your $6 million back

Hypothetical, our arithmetic. 5-year hold, 30% paydown, 8% profits-interest pool with a $15 million threshold. Breakeven is the exit multiple at which your stake equals $6,000,000. The preferred rows use the 8% compounding preference from the waterfall section below.

Your security Flat EBITDA ($3.0M) 5% growth ($3.83M) 10% growth ($4.83M)
Pari passu common 8.5x 6.7x 5.3x
Behind sponsor non-participating preferred 10.0x 7.9x 6.2x
Behind sponsor participating preferred 13.3x 10.4x 8.3x

This table is the quickest test of a structure. Pari passu common with 10% growth gets its cost back at an exit just above half the 10x entry. Behind a participating preferred with flat EBITDA, you need an exit more than three turns above entry just to recover your $6 million.

4 things the calculator does not model, and how to adjust

Hypothetical, our arithmetic. Each adjustment starts from the base case above: 15,000,000 units at $1.00, 6,000,000 of them yours.

Item Effect on your stake Adjustment Base case effect
Profits interests above a threshold Pool shares only in gains above the threshold Effective pool % = pool % × (1 − threshold ÷ equity before pool) 8% × (1 − $15.0M ÷ $42.6M) = 5.19%
Add-on funded with new equity above your entry price Your ownership % falls Ownership = your units ÷ total units after issuance Sponsor adds $2,500,000 at $1.50 per unit = 1,666,667 new units, 16,666,667 total. Your 6,000,000 units = 36.0%. Stake $14,556,630, 2.43x, 19.4% IRR
Exit transaction fees Banker, legal and other costs come off proceeds Subtract fees from exit EV before debt, then apply the pool threshold Fees 2% × $53,146,830 = $1,062,937. Equity before pool $41,583,893. Pool 8% × $26,583,893 = $2,126,711. Equity to capital holders $39,457,182. Your 40%: $15,782,873, 2.63x, 21.3% IRR
Dividend recap or interim distributions Cash arrives early, exit debt rises Model as a separate interim cash flow. The calculator's IRR assumes none Raises IRR, lowers exit equity by the recap debt still outstanding

The dilution row assumes the add-on bought with the new $2.5 million is already inside the 10% growth plan. Exit EV, exit debt and the $15 million threshold stay at base case, so exit equity to capital holders stays at $40,435,084 and only your share changes. That is the right test when the sponsor's growth rate already counts on acquisitions. Someone has to fund those acquisitions, and the choice of funding moves your stake.

Funding for the same $2.5M add-on (inside the growth plan) Exit debt Equity to capital holders Your ownership Your stake MOIC IRR
Already funded from cash flow (base case) $10,500,000 $40,435,084 40.0% $16,174,033 2.70x 21.9%
New debt, still outstanding at exit $13,000,000 $38,135,084 40.0% $15,254,034 2.54x 20.5%
New sponsor equity at $1.50 per unit $10,500,000 $40,435,084 36.0% $14,556,630 2.43x 19.4%

In the debt row, equity before pool is $40,146,830, and the pool takes 8% × $25,146,830 = $2,011,746. If an add-on lifts EBITDA above the base plan, exit equity rises and recovers part of either cost. Ask the sponsor which case its model uses and get pre-emptive rights so you can buy into new equity at the issue price.

Platforms grow by buying practices. Of the 1,029 PE-backed U.S. healthcare deals the Private Equity Stakeholder Project tracked in 2025, 664 were add-ons, 214 were growth investments and 151 were leveraged buyouts, a count PESP describes as likely an underestimate. Each add-on is funded with new debt, new equity or both. Run a 0% paydown case and a diluted case, and treat the base case as a ceiling until the sponsor shows its add-on funding plan.

Where your rollover sits in the waterfall

The calculator assumes one class of common equity. Many sponsor deals differ. The sponsor takes preferred units with an accruing return, or the rollover lands in a junior class, in a subsidiary below the holding company that gets sold, or in a holdco note. Each one changes the payout.

Rollover structure How it pays at the second sale How to model it
Common, pari passu with sponsor Pro rata with the sponsor from the first dollar Use the calculator as is
Common behind sponsor non-participating preferred Sponsor takes its accrued preference or converts to common, whichever pays it more Run both paths below and use the lower result for you
Common behind sponsor participating preferred Sponsor takes its preference, then also shares in the remainder as if converted Cuts value in every case
Junior class or subsidiary-level equity Paid after all senior classes and holdco debt Subtract senior claims from exit equity before applying your %
Holdco note or seller note Fixed interest and principal, no upside Model as debt at its stated rate

Worked example (hypothetical, our arithmetic): same deal, sponsor's $9 million held as 8% compounding preferred. The sponsor's preference after five years is $9,000,000 × 1.08^5 = $13,223,953. The weak case holds EBITDA flat at $3 million and exits at 9x. Distribution order:

  1. Exit EV pays the $10,500,000 of remaining debt.
  2. Profits interests take 8% of equity above the $15,000,000 threshold.
  3. Non-participating preferred: the sponsor compares its $13,223,953 preference with the 60% it would own if it converted, and takes the larger amount. If it takes the preference, it holds no common. Your units are then the only common, and you receive 100% of what is left. If it converts, you hold 40% of the common, the same as pari passu.
  4. Participating preferred: the sponsor takes its preference first. The remainder is then split 60% to the sponsor and 40% to you.
Step Base case (11x, 10% growth) Weak case (9x, flat EBITDA)
Exit EV $53,146,830 $27,000,000
Equity after debt $42,646,830 $16,500,000
Profits interests $2,211,746 $120,000
Equity to capital holders $40,435,084 $16,380,000
Sponsor's 60% if it converts $24,261,050 $9,828,000
Remainder after the $13,223,953 preference, before any split $27,211,131 $3,156,047
Participating case: sponsor's 60% of that remainder $16,326,679 $1,893,628
Participating case: your 40% of that remainder $10,884,452 $1,262,419
Your security Your base case stake MOIC Your weak case stake MOIC
Pari passu common (40% of equity to capital holders) $16,174,033 2.70x $6,552,000 1.09x
Behind non-participating preferred $16,174,033 (sponsor converts, you take 40%) 2.70x $3,156,047 (sponsor takes preference, you take 100% of the remainder) 0.53x
Behind participating preferred (you take 40% of the remainder) $10,884,452 1.81x $1,262,419 0.21x

In the base case the non-participating sponsor converts, because $24,261,050 beats its $13,223,953 preference. The structure costs you nothing there. In the weak case conversion would pay the sponsor only $9,828,000, so it takes the preference and leaves you the $3,156,047 remainder. A participating sponsor takes its preference and 60% of what is left in both cases, which is why it costs you $5.29 million even in the base case. Some LLC agreements pay profits interests only after the preference is returned. In that order the pool comes out of the common's share, and your weak case figures fall further. Get the capitalization table and the distribution waterfall from the draft LLC agreement before trusting any output. The Physician Rollover Equity Checklist lists the questions to ask.

Choosing the exit multiple

The exit multiple is the sponsor's call and the market's price. Three datasets bear on it. Each measures a different population and period, so read them separately and do not average across them.

Dataset Population and period Figures
PitchBook, reported by Sikich (Q3 2026) Healthcare M&A deals with reported multiples, 2024 to Q3 2026 Median EV/EBITDA 14.5x (2024), 13x (2025), 11.6x (2026 through Q3)
PitchBook, reported by Sikich (Q3 2026) PE-backed U.S. healthcare services buyouts, 2024 and 2025 Median 13.5x (2024), 13.6x (2025)
Buckhead FMV 187 U.S. healthcare services control deals with primary-source prices, January 2023 to October 2026. EBITDA medians come from only 68 deals with positive EBITDA across all four years Median 11.4x (2023), 9.7x (2024), 6.5x (2025), 9.1x (2026 through October)

Buckhead describes its yearly medians as "a band, not a trend" and attributes the 2025 dip to a smaller, more mid-market deal mix rather than a broad repricing. With 68 EBITDA observations over four years, each annual median rests on a small sample. Buckhead also notes its EBITDA medians lean toward larger deals, because large and public-company deals report EBITDA more often. Use the Buckhead band as a check on the downside case, not as a point estimate. Owners who roll because they expect better pricing later should put that view in an upside case.

Size is the stronger argument for a higher exit multiple. The worked example is a dental platform, so the relevant Sikich range is 9 to 11x for DSO platforms. That makes 11x the top of the range, not the middle. Sikich's indicative physician practice bands (Q3 2026) show how steep the size premium runs:

Practice EBITDA Indicative EV/EBITDA (Sikich, Q3 2026)
Below $1 million 5 to 7x
$1 million to $3 million 7 to 9x
$3 million to $5 million 9 to 11x
Above $5 million 11 to 13x

The base case grows EBITDA from $3.0 million to $4.8 million. Two more years at 10% reach $5.8 million, which falls in the above-$5 million band. Size moves the range. Specialty, growth rate, payer mix, customer concentration and deal structure set where a business lands inside it. Segment benchmarks are in Healthcare Valuation Multiples by Sector and Specialty.

Timing: who buys at the second sale

Exit windows open and close, and IRR pays for every extra year. Bain & Company's Global Healthcare Private Equity Report 2026 puts global healthcare PE exit value at an expected $156 billion in 2025, up from $54 billion in 2024. Bain expected more than 150 sponsor-to-sponsor deals in 2025, worth more than $120 billion. Of the 26 North American healthcare PE deals above $1 billion through November 2025, more than 70% were sponsor-to-sponsor sales. The second buyer can also be a strategic. Bain cites Cencora's acquisition of Retina Consultants of America from Webster Equity Partners and Cardinal Health's GI Alliance acquiring Solaris Health from Lee Equity Partners.

Many physician rollover holders are mid-hold now. In the AMA's 2024 Physician Practice Benchmark Survey, 6.5% of U.S. physicians worked in PE-owned practices, up from about 4.5% in 2020 and 2022, and 38% of those said their practice had been acquired in the past five years.

Regulatory review at the second sale can lengthen the hold. Some states review certain healthcare transactions, as Latham & Watkins' 2026 state regulatory review describes, and these rules change. Ask your attorney which reviews could apply to your deal. Any added time lowers IRR at the same exit value. In the base case, one extra year with no growth takes IRR from 21.9% to 18.0%. Our healthcare M&A process guide covers how reviews affect timing.

Tax: compare offers after tax

The calculator shows pre-tax values. Deferral is what makes rollover efficient. Rollovers are commonly structured to defer tax on the rolled portion until the second sale, while the cash portion is taxed at closing. Deferral is not automatic. The holding company's tax classification, any cash or debt relief you receive in the exchange and how the contribution is documented all affect the result. Ask the buyer for its structure memo early and model both cases until the treatment is settled.

A taxable roll costs less than it first appears, because the tax you pay at close gives you basis in the rolled units. That basis cuts the gain at the second sale.

Worked example (hypothetical, our arithmetic). Base case stake of $16,174,033. Assumptions, not market data: zero starting basis in the rolled practice equity, and a single 25% combined rate at both dates.

Deferred roll Roll taxable at close
Tax at close $0 $1,500,000
Basis in rolled units $0 $6,000,000
Gain at second sale $16,174,033 $10,174,033
Tax at second sale (25%) $4,043,508 $2,543,508
Total tax paid $4,043,508 $4,043,508
Net after tax at second sale $12,130,525 $13,630,525

Total tax is the same. The taxable roll costs you two things. First, you pay $1.5 million five years early, out of your cash proceeds, on equity you cannot sell. At an 8% opportunity rate, that timing costs $1.5 million × (1.08^5 − 1) = $703,992. Second, rates can change between close and exit, in either direction. In a downside case the taxable roll also leaves a capital loss if the stake ends below its $6 million basis, and that loss is worth only what you can offset with other gains.

Sizing the roll: cash at close against the stake at exit

The rollover amount is often the one input you can still move. On the same $30 million deal, every dollar you roll is a dollar of sponsor cash you do not receive at close. Assume you own 100% of the practice, carry no existing debt and pay no fees, so your cash at close is the $30 million price less your roll. The entry equity stays at $15 million and the pool threshold stays at $15 million, so only your ownership share changes.

Hypothetical, our arithmetic. Pari passu common, 5-year hold, 30% paydown, pre-tax. Base case is 11x and 10% growth. Weak case is 9x and flat EBITDA.

Rollover amount Share of price Cash at close Ownership Base case stake Base case total (cash plus stake) Weak case stake Weak case total (cash plus stake)
$3,000,000 10% $27,000,000 20% $8,087,017 $35,087,017 $3,276,000 $30,276,000
$6,000,000 20% $24,000,000 40% $16,174,033 $40,174,033 $6,552,000 $30,552,000
$9,000,000 30% $21,000,000 60% $24,261,050 $45,261,050 $9,828,000 $30,828,000

Three readings follow from the table:

Use the calculator to rerun this table with your own price, debt and structure before you agree a rollover percentage in the LOI.

Three areas bear directly on rollover equity. If you will refer patients to a platform you partly own, federal referral and self-referral rules may affect that ownership, so ask your attorney how they apply to your deal. HHS OIG and CMS publish background on these rules. Corporate practice of medicine and dentistry rules shape whether you hold equity in the practice entity, the MSO or a holding company above both. The units you receive are securities, so offering rules govern how they are issued to you. Have your attorney look into each one for your deal. Our guides on healthcare compliance due diligence and physician investors who refer cover the business side.

The rollover data room: 7 documents to request before you sign

Every number in the calculator should trace to a document the sponsor has given you. If a document is missing, the matching input is a guess. Ask for these before exclusivity ends.

Document Calculator input it supports What to check in it Worked example figure (hypothetical)
Sources and uses table Debt at close, entry equity Debt, sponsor cash and rollover add up to the price plus fees $15M debt, $9M sponsor cash, $6M roll
Pro forma capitalization table Ownership % Total units at close, including co-investor, management and fee-funded units 6,000,000 of 15,000,000 units, 40%
Draft LLC agreement Waterfall position Your unit class, any sponsor preference, its rate and whether it participates, and where the pool is paid Pari passu common 2.70x, behind a participating preferred 1.81x
Incentive plan term sheet Management pool Pool size, threshold mechanics, vesting and what happens to forfeited units 8% pool above a $15M threshold, 5.19% effective
Credit agreement summary Debt paid down by exit Required amortization, cash sweep and room to borrow more for add-ons 30% paydown. At 0% paydown the stake falls to $14.52M
Sponsor's base case model Growth, years to sale, exit multiple Which add-ons are inside the growth rate and how each is funded 10% growth, 5 years, 11x
Fund vintage and remaining term Years to second sale How many years the fund has left and whether extensions are likely A 7-year hold with flat growth drops IRR from 21.9% to 15.2%

Two free public checks add to the packet. Search the sponsor's fund name in SEC EDGAR full-text search. Form D notices show when a private fund began raising, which dates the fund's vintage and the pressure it faces to sell. If a banker is running the sale, look up the firm and the individual bankers in FINRA BrokerCheck for registration and disclosure history.

Then run three cases rather than one. Enter the sponsor's model as given. Rerun it at 0% paydown with the diluted ownership from any planned add-on equity. Find your structure's row in the breakeven table and compare it with the entry multiple. If the three cases tell different stories, the gap is what you are negotiating over.

What to negotiate before you roll: 8 terms

A minority rollover holder does not control the second sale. The LLC agreement decides whether you receive the sponsor's price, on the sponsor's terms, at the sponsor's time. These eight terms carry most of the value modeled above:

Raise every missing term at the LOI stage. Terms are hardest to change after exclusivity. The LOI and Term Sheet Red Flags checklist covers the language to look for.

Roll more or roll less: a decision table

Factor Supports rolling more Supports rolling less
Security Same class and price as sponsor Junior class, or behind sponsor preferred
Breakeven exit multiple Well below the entry multiple At or above the entry multiple
Growth plan Funded add-on pipeline with your practice as an anchor Growth depends on acquisitions not yet identified
Add-on funding Debt or cash flow, with pre-emptive rights on any new equity New equity issued without your right to participate
Sponsor timing Early in the fund's life, with room to hold for growth Late in the fund's life, with pressure to sell on a set date
Tax Deferral confirmed in the structure memo Roll taxable at close and paid from your cash proceeds
Your liquidity Cash at close covers taxes, debt and personal needs You need the rolled dollars within the hold period
Information rights Quarterly financials and annual marks No reporting commitment
Your role after close You drive EBITDA growth at the platform You plan to reduce clinical time or leave

Run the breakeven table first. If your structure needs an exit above entry just to return your cost, the roll is a bet on multiple expansion and should be sized like one.

Rollover compared with the other deferred pieces of price

Deferred component What drives the payout Upside cap
Rollover equity Platform EBITDA, exit multiple, debt, waterfall None
Earnout Your practice hitting set targets Fixed maximum
Escrow or holdback Indemnity claims during the survival period Amount held

Earnouts are more common than they were. SRS Acquiom's 2026 study found U.S. private equity buyers in its deal data used earnouts in 24% of 2025 deals, up from 13% in 2014 to 2022. A rollover and an earnout in the same offer put two layers of price at risk.

Next step: pair this with the proceeds calculator

This page values the stake you keep. The Healthcare Deal Proceeds Calculator shows the cash you take home at close after debt payoff, escrow, fees and the rollover itself. Run both on the same offer to compare cash now with value later. If the headline price is still open, start with the Practice Valuation Calculator. For how rollover sits alongside earnouts and MSO structures, read Healthcare Deal Structures.

Questions owners ask about rollover equity

Is rollover equity worth the same as the cash portion of the price?

No. Cash at close is certain and paid now. Rollover is an illiquid minority stake. Its value depends on EBITDA growth, the exit multiple, remaining debt, dilution, where your security sits in the waterfall and when the sponsor decides to sell. It can return several times its entry value or close to nothing. Treat rolled dollars as a private equity investment you make alongside the buyer.

What rollover percentage is typical in healthcare deals?

No public dataset reports a reliable median, so anchor on structure and size. FOCUS Investment Banking's 2026 dermatology benchmarks show platform-ready dermatology practices, typically with $5 million or more of EBITDA, often receiving 70% or more of the price in cash at close, with meaningful rollover. That leaves roughly 30% or less of the price for rollover and any other deferred pieces. Measure your roll two ways. In this page's example, $6 million is 20% of the $30 million price but 40% of the $15 million entry equity, and the second figure sets your ownership.

What if my rollover is not in the same security as the sponsor's equity?

Then the calculator overstates your value. In this page's hypothetical, a sponsor 8% non-participating preferred cuts your $6 million roll from $6.55 million to $3.16 million in the weak case. A participating preferred cuts your stake in the base case too, from $16.17 million to $10.88 million. If the rollover is a holdco note or seller note, model it as debt with a fixed return, not as equity.

Is the rolled portion taxed at closing?

Often not. Rollovers are commonly structured to defer tax on the rolled portion until the second sale, while the cash portion is taxed at closing. Deferral is not automatic. The entity type, the cash and debt in the exchange and how the contribution is built all affect it. If the roll is taxable, you take a matching basis in the rolled units, so most of the early tax comes back as lower tax at the second sale. The real cost is paying cash now on equity you cannot sell, plus the time value of that cash.

How does the management incentive pool reduce my rolled stake?

Sponsors reserve equity for executives and key physicians, usually as profits interests or options. Profits interests generally share only in value above a threshold set when they are granted. In this page's base case, an 8% pool sharing in value above a $15 million threshold takes $2.21 million, or 5.19% of exit equity, not 8%. Ask for the pool size, the threshold mechanics, the vesting terms and where the pool sits in the waterfall.

What exit multiple should I enter?

Start with the entry multiple and run a case one to two turns lower. PitchBook's median healthcare M&A multiple, reported by Sikich, fell from 14.5x in 2024 to 11.6x in 2026 through the third quarter. Buckhead FMV's yearly medians for U.S. healthcare services control deals moved in a band between 6.5x and 11.4x from 2023 to October 2026, on small annual samples. Count multiple expansion as upside unless EBITDA growth moves the business into a higher size band.

Sources